Atara Biotherapeutics (ATRA) came out with a quarterly loss of $2.93 per share ... estimates three times over the last four quarters. The sustainability of the stock's immediate price movement based ...

THOUSAND OAKS, Calif. (AP) — THOUSAND OAKS, Calif. (AP) — Atara Biotherapeutics Inc. (ATRA) on Tuesday reported a loss of $21.9 million in its third quarter. On a per-share basis, the Thousand Oaks, ...

Analysts are estimating that Atara Biotherapeutics will report an earnings per share (EPS) of $-1.93. Atara Biotherapeutics ...

Buy ATRA near 8.11 target 12.98 stop loss @ 8.09 Details The technical summary data tells us to buy ATRA near 8.11 with an upside target of 12.98. This data also tells us to set a stop loss @ 8.09 to ...

The 36-month beta value for ATRA is at 0.45. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 3 rating it as “overweight,” 1 as “hold,” and 0 as “sell.” The public float ...

Yatra Online, Inc. (YTRA) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to loss of $0.02 per share a year ago. These figures ...

Copyright © 2024 MarketWatch, Inc. All rights reserved.

Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.30. This compares to loss of $0.35 per share a year ago. These ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop ...